- Protein Name
- Eukaryotic translation initiation factor 2-alpha kinase 3
- Gene Name
- EIF2AK3
- Organism
-
Homo sapiens
- Function
- Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability. Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function.
Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
MPP |
3 |
3 |
3.0 |
DRS |
17 |
2 |
10.0 |
MT3 |
23 |
2 |
15.0 |
AAS |
10 |
5 |
7.0 |
PDIG |
14 |
4 |
5.0 |
ATP |
21 |
2 |
14.5 |
PDB ID |
Maximum Consensus Site Population |
MPP site |
DFG site |
PIF site |
DRS site |
DEF site |
EDI site |
MT3 site |
AAS site |
LBP site |
CMP site |
PDIG site |
ATP site |
PMP site |
Total Druggable Structures per Site |
0 |
0 |
0 |
1 |
0 |
0 |
8 |
0 |
0 |
0 |
0 |
2 |
0 |
4X7O
|
0 |
0 |
0 |
11 |
0 |
0 |
20 |
6 |
0 |
0 |
14 |
13 |
0 |
4X7K
|
0 |
0 |
0 |
10 |
0 |
0 |
19 |
5 |
0 |
0 |
0 |
0 |
0 |
4X7N
|
0 |
0 |
0 |
8 |
0 |
0 |
16 |
5 |
0 |
0 |
0 |
15 |
0 |
4X7L
|
0 |
0 |
0 |
9 |
0 |
0 |
17 |
0 |
0 |
0 |
0 |
21 |
0 |
4X7J
|
0 |
0 |
0 |
13 |
0 |
0 |
23 |
0 |
0 |
0 |
0 |
15 |
0 |
AFQ9NZJ5
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4G31
|
3 |
0 |
0 |
17 |
0 |
0 |
16 |
10 |
0 |
0 |
0 |
13 |
0 |
4G34
|
0 |
0 |
0 |
15 |
0 |
0 |
11 |
8 |
0 |
0 |
0 |
18 |
0 |
4X7H
|
0 |
0 |
0 |
9 |
0 |
0 |
23 |
7 |
0 |
0 |
5 |
0 |
0 |
4M7I
|
0 |
0 |
0 |
13 |
0 |
0 |
17 |
10 |
0 |
0 |
4 |
14 |
0 |